of Florida Medicaid administrative claims, we identifi ed the fi rst documented psoriasis diagnosis ("index diagnosis") among adult (aged 18 years) enrollees. "Targeted treatments," those FDA-approved for psoriasis by June 30, 2006, were oral systemics (acitretin, cyclosporine, methotrexate) and biologics (alefacept, efalizumab, etanercept). Patients in "active treatment" received 2 fi lls of the same targeted treatment within 45 days during the year following index diagnosis. RESULTS: Among 3,137,110 adult enrollees, 7,571 (0.24%) received an index diagnosis of psoriasis. Of these, 173 (2.3%) patients received active treatment; they were predominantly female (67.6%) and Caucasian (50.3%). There were 54 (31.2%) patients aged 18-39 years, 81 (46.8%) aged 40-59 years, and 38 (22.0%) aged 60 years. Among those actively treated, 63.6% (110/173) received oral systemics [24.3% (42/173) . Mean (SD) doses were: acitretin 26.6 (11.0) mg/day, cyclosporine 130 (61.0) mg/day (equivalent to 1.5 and 1.7 mg/kg/day for average males and females in the United States, respectively), methotrexate 17.5 (14.7) mg/week, and etanercept 67.2 (26.6) mg/week; alefacept and efalizumab had insuffi cient data for analysis. Median doses were: acitretin 25 mg/day, cyclosporine 100 mg/day (equivalent to 1.1 and 1.3 mg/kg/day for average U.S. males and females, respectively), methotrexate 14.7 mg/week, and etanercept 49.7 mg/week. Eighty-one percent of patients received acitretin 25 mg/day, 67% received cyclosporine 100 mg/day, 72% methotrexate 17.5 mg/week, and 54.5% etanercept 50 mg/week. CONCLUSIONS: Although the number of treatments for moderate-to-severe psoriasis is burgeoning, little is known about patient characteristics and patterns of care within a "real world" setting (i.e., absent clinical research protocol requirements). Internet panel, and were reported to have physician-diagnosed IBD. Survey respondents were aged 18 years. RESULTS: A total of 500 patients with CD completed the survey. Nearly half (43.5%) reported being diagnosed within a year of experiencing symptoms, and another 20.4% were diagnosed within 1-2 years. Most patients presented with moderate (36.2%) or severe (45.6%) disease at diagnosis. More than half (56.8%) began drug treatment within a month of diagnosis. When evaluating treatment patterns, 79.6% of patients used more than one treatment, and most changed to their second treatment within one year. Steroids (52.0%) and 5-aminosalisylic acids (54.0%) are the most common initial treatment options. Immunomodulators and biologics are not used often as fi rst line therapy, but their use increases with the number of treatments. More than half of patients (53.0%) had the dose of their initial treatment increased, but increasing dose becomes a less common strategy for future treatments. Paradoxically, as the number of treatments increase, the number of patients experiencing surgery and reporting severe disease decreases. CONCLUSIONS: The majority of CD patients are diagnosed and treated within a year of experiencing symptoms. Multiple treatments are common, with self-reported disease severity decreasing with an increase in the number of treatments, especially when immunomodulators and biologics have been utilized. Research identifying the most effective treatments that control disease and decrease surgery, and the optimal time when they should be used during the natural course of the disease, is needed.
PSY47 CROHN'S DISEASE TREATMENT PARADIGM
Waters HC 1 , Bolge SC 2 , Freedman D 2 , Piech CT 1 1 Centocor Ortho Biotech Services, LLC, Horsham, PA, USA, 2 Consumer Health Sciences International, Princeton, NJ, USA OBJECTIVES: This study aimed to understand patterns of treatment in patients with CD, including the initiation of treatment and changes of regimens over time.
METHODS:
Cross-sectional data were collected via the Infl ammatory Bowel Disease (IBD) Study Project during Q3 2008. Study participants were recruited from an Internet panel, and were reported to have physician-diagnosed IBD. Survey respondents were aged 18 years. RESULTS: A total of 500 patients with CD completed the survey. Nearly half (43.5%) reported being diagnosed within a year of experiencing symptoms, and another 20.4% were diagnosed within 1-2 years. Most patients presented with moderate (36.2%) or severe (45.6%) disease at diagnosis. More than half (56.8%) began drug treatment within a month of diagnosis. When evaluating treatment patterns, 79.6% of patients used more than one treatment, and most changed to their second treatment within one year. Steroids (52.0%) and 5-aminosalisylic acids (54.0%) are the most common initial treatment options. Immunomodulators and biologics are not used often as fi rst line therapy, but their use increases with the number of treatments. More than half of patients (53.0%) had the dose of their initial treatment increased, but increasing dose becomes a less common strategy for future treatments. Paradoxically, as the number of treatments increase, the number of patients experiencing surgery and reporting severe disease decreases. CONCLUSIONS: The majority of CD patients are diagnosed and treated within a year of experiencing symptoms. Multiple treatments are common, with self-reported disease severity decreasing with an increase in the number of treatments, especially when immunomodulators and biologics have been utilized. Research identifying the most effective treatments that control disease and decrease surgery, and the optimal time when they should be used during the natural course of the disease, is needed.
PSY48 IMPACT OF DIFFERENT WEIGHT CONTROL MEASURES TAKEN BY THE STUDENTS ON THEIR WEIGHT
Sreepada A p University of Louisville, Louisville, KY, USA OBJECTIVES: Body Mass Index (BMI) is useful to estimate the overall health in comparison with the person's weight and height. BMI can be infl uenced by the different weight control behaviors like exercise, drinking more water, eating low fat food etc. The purpose of this project is to analyze various weight control measures tried by the students and their impact on students' weight. The study attempts to investigate their preferences among the weight control behaviors based on gender.
METHODS:
The data is taken from a survey that was conducted by Health Behavior in SchoolAged Children (HBSC) during the years 2001-2002 on 11 to 15 years old school going children. The dataset is prepared and a sample with 2000 observations is selected for the analysis. The variables under study are BMI_COMP,Gender and the group of different Weight control measures.The bar graphs are plotted for each weight control behavior against Gender and BMI_COMP to understand the association between the different weight control measures that are employed by the students and their recorded BMI_COMP. Kernel Density Estimator is generated using SAS code node for better visualization and to enable the comparison between the different weight control measures. RESULTS: Exercise, drinking more water, eating more fruits and vegetables are very effective and most popular among the students. Girls tend to skip meals more than boys, while more boys undertake exercise to control weight. Surprisingly the least favored measures like vomiting, fasting, using pills are adopted by more number of girls than boys. CONCLUSIONS: Obesity in early adolescence is a serious health issue all over the globe. It is very important for children to choose proper methods to control weight. This project gives useful insights on the different perspectives of girls and boys in choosing the right weight control strategy.
PSY49 DETERMINANTS OF MEDICAL SERVICES UTILIZATION IN CHRONIC NONCANCER PAIN PATIENTS
Puenpatom RA p , Victor TW Endo Pharmaceuticals, Chadds Ford, PA, USA OBJECTIVES: To examine the determinants of demand for health service utilization in a chronic noncancer pain population. METHODS: Data were collected from the Opioid Utilization Study (OPUS), an ongoing 1-year, multicenter, prospective, observational cohort study of patients with chronic non-cancer pain receiving opioids. Negative binomial models were used to evaluate determinants of medical service utilization. Dependent variables were: number of medical visits and utilization of alternative/complementary therapy (i.e. acupuncture and massages). Explanatory variables were: physical (PF) and mental function (MF) scores from the Short Form 12 Health Survey (SF-12), mean cost of medical visits, net household income, insurance type, sex, race and age. RESULTS: Of 811 patients, 61.4% were female and 90.9% were white, 94.3% had experienced chronic pain for 1 year. The mean number of medical visits was 2.9 (SD 3.6) per month for females and 2.6 (SD 3.6) for males. On average, patients visited pain clinics once a month (mean 0.9, SD 1.17), and visited primary care physicians once every other month. MF, race, income, and mean cost per visit was statistically signifi cant (p .05). Patients with lower MF were more likely to have higher rates of medical utilization (P 0.001). A one unit increase in MF score was associated with a 1.1% decrease in the rate of medical visits. However, there was no evidence that PF was associated with the rate of medical visits. The mean cost of medical services was statistically signifi cant (p 0.001). A $10 increase in cost decreased the rate of medical visits by 2%. Lower income patients were more likely to consume higher medical services compared to the high income group (p 0.01). CONCLUSIONS: MF measures may be useful in predicting medical care utilization. Health care costs were negatively associated with health utilization as is predicted by demand theory.
